Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457212 | 0.92 | KCNA5 (0.42) | CYP19A1KMT2AKCNA5OXTR | |
| SCHEMBL4469601 | 0.89 | KCNA5 (0.42) | CYP19A1KMT2AMEN1KCNA5SMN1; SMN2 | |
| SCHEMBL4461835 | 0.89 | CYP19A1 (0.40) | CYP19A1KMT2AKCNA5OXTR | |
| SCHEMBL4458827 | 0.89 | CYP19A1 (0.43) | CYP19A1KCNA5CYP3A4CYP3A5MAPT | |
| SCHEMBL4457675 | 0.88 | KCNA5 (0.41) | CYP19A1KCNA5OXTRCRHR1 | |
| SCHEMBL4466454 | 0.85 | CYP19A1 (0.48) | CYP19A1KCNA5OXTRCYP3A4 | |
| SCHEMBL14435025 | 0.85 | KCNA5 (0.38) | CYP19A1KCNA5OXTR | |
| SCHEMBL4470602 | 0.82 | KCNA5 (0.35) | CYP19A1KMT2AMEN1KCNA5OXTR | |
| SCHEMBL4457667 | 0.82 | KMT2A (0.39) | CYP19A1KMT2AMEN1KCNA5OXTR | |
| SCHEMBL4456687 | 0.82 | POLB (0.39) | CYP19A1KMT2AMEN1KCNA5OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | CYP19A1 4359/4885KMT2A 130/4885MEN1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.